1200-05-1

Basic information

• Product Name: 4-AMINOMETHYLPHENYLACETIC ACID
• Synonyms: 2-(4-(AMINOMETHYL)PHENYL)ACETIC ACID;4-AMINOMETHYLPHENYLACETIC ACID;4-Aminomethylphenylacetic acid, HCl;Benzeneacetic acid, 4-(aMinoMethyl)-
• CAS NO: 1200-05-1
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Product Categories: pharmacetical
• Mol File: 1200-05-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 336.7 °C at 760 mmHg
• Flash Point: 157.4 °C
• Appearance: /
• Density: 1.206 g/cm³
• Vapor Pressure: 4.32E-05mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.04±0.10(Predicted)
• CAS DataBase Reference: 4-AMINOMETHYLPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINOMETHYLPHENYLACETIC ACID(1200-05-1)
• EPA Substance Registry System: 4-AMINOMETHYLPHENYLACETIC ACID(1200-05-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Hazardous Substances Data: 1200-05-1(Hazardous Substances Data)

Usage

General Description

4-Aminomethylphenylacetic acid, also known as 4-AMPA, is a chemical compound with the molecular formula C9H11NO2. It is an organic compound with a phenylacetic acid backbone, and a primary amine and a carboxylic acid functional group. 4-AMINOMETHYLPHENYLACETIC ACID is commonly used as a starting material for the synthesis of various pharmaceuticals, including non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines. It has also been studied for potential applications in the treatment of neurological disorders and as a precursor for the synthesis of other organic compounds. Additionally, 4-AMPA has been identified as a potential precursor for the synthesis of new antibiotics and antimicrobial agents.

InChI:InChI=1/C9H11NO2/c10-6-8-3-1-7(2-4-8)5-9(11)12/h1-4H,5-6,10H2,(H,11,12)

Upstream product

• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 
• 5462-71-5 4-cyanophenylacetic acid 
• 1528-41-2 ethyl 4-cyanophenylacetate 
• 103-82-2 phenylacetic acid 
• 62910-48-9 ethyl 2-[4-(aminomethyl)phenyl]acetate 
• 117885-63-9 {4-[(2-chloro-acetylamino)-methyl]-phenyl}-acetic acid 
• 109093-38-1 (4-phthalimidomethyl-phenyl)-acetic acid 
• 56066-91-2 4-chloromethylphenylacetic acid 
• 13737-36-5 4-bromophenylacetic acid 

Downstream Products

• 1610413-97-2 C₃₄H₅₄N₄O₁₀ 
• 1610414-00-0 C₃₃H₄₅N₇O₁₇S 
• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 
• 1257585-83-3 C₁₅H₁₆N₄O₃S 
• 1257585-82-2 C₁₆H₁₆N₂O₄S 
• 1257585-81-1 C₉H₁₂N₂O*ClH 
• 1257585-80-0 C₁₄H₂₀N₂O₃ 
• 143774-31-6 2-<4-<<<(tert-butyloxy)carbonyl>amino>methyl>phenyl>-5-hexynoic acid 
• 143774-33-8 2-<4-(guanidinomethyl)phenyl>-5-hexynoic acid 
• 143774-32-7 2-<4-(aminomethyl)phenyl>-5-hexynoic acid 
• 176504-00-0 (S)-2-tert-Butoxycarbonylamino-3-(2-{4-[(9H-fluoren-9-ylmethoxycarbonylamino)-methyl]-phenyl}-acetylamino)-propionic acid 

Relevant articles and documents

A new strategy applied to the synthesis of an α-helical bicyclic peptide constrained by two overlapping i, i+7 side-chain bridges of novel design

A conformationally constrained, bicyclic, 14-residue peptide containing two overlapping i, i+7 side-chain bridges has been synthesized. The design of the side-chain linkage, which is built around a p-substituted benzene ring for rigidity, and the solid-phase approach applied to the peptide synthesis, are both new. A Boc/Benzyl peptide chain assembly method was combined with Fmoc/OFm orthogonal side-chain deprotection and solid-phase cyclization to form the first side-chain lactam bridge. A 2-(2-pyridyl)ethyl group (2-Pet), activated by methylation with CH3I in DMF, was then used in combination with Fmoc to allow a second orthogonal side-chain deprotection and solid-phase cyclization to form the second bridge. The circular dichroism spectrum of the product indicates that it is highly helical.

HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.